MiR-SNPs as Markers of Toxicity and Clinical Outcome in Hodgkin Lymphoma Patients
Figure 3
DFS and OS according to the combination of TRBP and XPO5 genotypes. Patients with both the XPO5 AA/CC and TRBP TT/TC genotypes had the worst prognosis. (A) DFS was 74 months (95% CI, 54–94) for patients with the unfavorable combination, compared to 114 months (95% CI, 102–126) for those with other combinations (P = 0.008). (B) OS was 103 months (95% CI, 86–120) for patients with the unfavorable combination and 135 months (95% CI, 128–143) for those with other combinations (P = 0.008).